Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01224067 · ClinicalTrials.gov registry record · Phase 4
Adjunctive Quetiapine in the Treatment of Refractory Social Anxiety Disorder in Adults
A Phase 4 study of Social Anxiety Disorder, sponsored by Cambridge Health Alliance.
- Completed
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT01224067: Completed Phase 4 study of Social Anxiety Disorder, sponsored by Cambridge Health Alliance.
NCT01224067 is a Phase 4 study of Social Anxiety Disorder that has completed, run by Cambridge Health Alliance. The registered enrollment target is 40 participants, below the 159-participant average among 32 other Social Anxiety Disorder trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01224067, a Phase 4 study of Social Anxiety Disorder, has completed, sponsored by Cambridge Health Alliance.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a 16-week research study in which participants suffering from Social Anxiety Disorder (SAD) will receive Sertraline (a medication FDA approved for the treatment of SAD) for the first 8 weeks. If a participant remains symptomatic, he/she will enter the second phase of the study in which he/she continues taking Sertraline but also randomly receives either Seroquel or placebo in conjunction with Sertraline for additional 8 weeks. The purpose of this study is to determine the efficacy of adjunctive Seroquel in treating SAD.
Primary Outcome
Change from Baseline to Endpoint of social anxiety symptoms after 8 weeks of treatment. Assessed weekly throughout the study for a total of 8 weeks.
Conditions Studied
Interventions
- DRUG Quetiapine
Study Locations (1)
Massachusetts
- Cambridge Health Alliance - Cambridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2006-03 |
| Est. Completion | 2008-10 |
| Phase | Phase 4 |
What the finished NCT01224067 record still lists
NCT01224067 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 159-participant average among 32 other Social Anxiety Disorder trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Social Anxiety Disorder appearing as the primary indexed condition, and to 1 intervention - of which Quetiapine is the first listed.
NCT01224067 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01224067 about?
NCT01224067 is a clinical study titled "Adjunctive Quetiapine in the Treatment of Refractory Social Anxiety Disorder in Adults". This is a 16-week research study in which participants suffering from Social Anxiety Disorder (SAD) will receive Sertraline (a medication FDA approved for the treatment of SAD) for the first 8 weeks. If a participant remains symptomatic, he/she will enter the second phase of the study in which he/sh...
What is the current status of trial NCT01224067?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2006-03. Estimated completion is 2008-10.
What conditions does trial NCT01224067 study?
This clinical trial studies the following conditions: Social Anxiety Disorder.
What interventions are being tested in trial NCT01224067?
The interventions under investigation include: Quetiapine (DRUG).
Who is sponsoring clinical trial NCT01224067?
This trial is sponsored by Cambridge Health Alliance, which has 45 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01224067 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Social Anxiety Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01224067's enrollment target sits among peer trials
40 29th of 32 the lowest of 32 other Social Anxiety Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Social Anxiety Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study To Evaluate The Effects Of Gabitril™ In Patients With Social Anxiety Disorder
COMPLETED · Phase 4
-
Validating an Autonomous Interactive Internet-Based Delivery of an Empirically Supported Cognitive Behavioral Therapy for Comorbidity
RECRUITING · NA
-
Individual Factors of CBT Underlying Success
RECRUITING · NA
-
A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder
RECRUITING · Phase 2
-
Neurofeedback Enhanced Cognitive Reappraisal Training - Phase 4
RECRUITING · NA
-
Very Brief Exposure: Development of a Novel Exposure Modality for Social Anxiety Disorder in Transition-Age Youth
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia